TG Therapeutics, Inc. announced its ranking as the number one fastest-growing company in North America on the 2024 Deloitte Technology Fast 500 list. This prestigious recognition highlights the company's exceptional growth trajectory within the technology, media, telecommunications, life sciences, fintech, and energy tech sectors.
The company's impressive growth between fiscal years 2020 and 2023 was primarily fueled by the robust revenues generated from BRIUMVI. BRIUMVI, approved in December 2022, is a treatment for adult individuals with relapsing forms of multiple sclerosis.
This acknowledgment underscores the commercial success of BRIUMVI and the company's effective strategy in bringing its treatment to patients. The ranking reflects the significant market penetration and adoption of its flagship product.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.